Zunsemetinib and capecitabine for breast cancer with bone spread
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called zunsemetinib combined with the chemotherapy capecitabine for people with hormone receptor-positive, HER2-negative breast cancer that has spread to the bones. The goal is to see if this combination can better control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that is hormone receptor-positive and HER2-negative, and it has spread to other parts of the body (metastatic).
- You have cancer in your bones that is growing or getting worse, or you don't have bone metastases yet (for the first phase of the study).
- You have had no more than one type of chemotherapy for metastatic disease, and you have already tried hormone therapy with a CDK4/6 inhibitor.
- You are healthy enough to be up and about (ECOG performance status 0, 1, or 2) and have a life expectancy of at least 12 weeks.
- Your blood counts and organ function are adequate (kidney, liver, and calcium levels within normal limits).
- You agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests whether adjusting the dose of the oral chemotherapy capecitabine over time can control metastatic breast cancer that is estrogen-receptor positive (ER+) and HER2−. It is designed for patients who are starting capecitabine or have just started it, and the study will monitor blood changes and tumor response closely.
This trial is testing a combination of two targeted drugs (zanidatamab and tucatinib) plus chemotherapy for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It's for those who have already had at least one other anti-HER2 treatment but no more than three.
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Hear when a new Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.